You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Novel Small Molecule Therapeutic for Alcoholic Chronic Pancreatitis
SBC: Angion Biomedica Corp. Topic: NIAAADESCRIPTION (provided by applicant): Chronic Pancreatitis (CP) is characterized by continuous or recurrent inflammation of the pancreas that leads to permanent destruction of the pancreas resulting in exocrine and endocrine insufficiency. CP is a common disorder associated with significant morbidity and mortality with an incidence of 8.2 and a prevalence of 27.4 per 100 000 population. The etiolog ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
PRECLINICAL TESTING OF HUMAN GHRELIN AND GROWTH HORMONE FOR SEPSIS IN THE ELDLY
SBC: THERASOURCE, LLC Topic: NIADESCRIPTION (provided by applicant): The ultimate goal of our proposal is to develop a novel therapeutic approach that will save lives of aged septic patients. Sepsis is the most common cause of death in the non-cardiac intensive care units (ICU). It is particularly a serious problem in the geriatric population. The elderly (e 65 years of age) accounts for 12% of the US population but 65% of sepsi ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Antifungal Compound Discovery from Metagenomes
SBC: LUCIGEN CORPORATION Topic: NIAIDDESCRIPTION (provided by applicant): There is societal need for new compounds in our arsenal of defenses against fungal pathogens, many of which are increasingly resistant to existing therapeutics. The best possible source for new antifungal compounds withpotentially novel mechanisms of action is within natural environments, particularly soils, which have the greatest diversity of microbial life. ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development, Production and Testing of VLP based Respiratory Syncytial Virus (RSV
SBC: TECHNOVAX INC Topic: NIAIDDESCRIPTION (provided by applicant): The goal of this proposal is to develop a safe and efficacious virus-like particle (VLP) based-respiratory syncytial virus (RSV) vaccine to prevent the disease caused by this pathogen. The respiratory illnesses provokedby RSV in infants, children and the elderly are of global economical and public health impact. A recent worldwide estimate [5] indicates that ov ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Therapeutic for Radiation Induced Lung Injury
SBC: Angion Biomedica Corp. Topic: NIAIDDESCRIPTION (provided by applicant): Nuclear accidents and terrorism present a serious threat for causing mass-casualty scenarios. In radiation events, many people receive non-uniform whole-body or partial-body irradiation. The risk of exposure to ionizingradiation due to terrorist activities could result in acute injury as well as long-term adverse health effects in thousands of people. The lung ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Novel system for sensitive detection of botulinum neurotoxins
SBC: ALPHA UNIVERSE LLC Topic: NIAIDDESCRIPTION (provided by applicant): The existence of terrorist organizations around the world, along with their ability to recruit expertise from physicians and scientists, poses an increasing threat of bioterrorist attack to society. In order to reduce the consequences of such an attack or even prevent it, new systems for detection of biothreat agents are necessary. Currently existing express ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil
SBC: ADJUVANCE TECHNOLOGIES INC. Topic: NIAIDDESCRIPTION (provided by applicant): Antitumor and anti-infectious disease vaccines require adjuvants in order to obtain optimal immunogenicity and therapeutic and protective efficacy. QS-21 is a natural saponin fraction that significantly out-performs other adjuvants in eliciting productive antibody and T-cell responses. It has remained the adjuvant of choice and has proven it's potency as i ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Optimization of an innate immune stimulating adjuvant for an HIV DNA vaccine
SBC: PROFECTUS BIOSCIENCES, INC. Topic: NIAIDDESCRIPTION: There is a growing consensus that protection against HIV infection will require BOTH antiviral antibody responses as well as polyfunctional CD4+ and CD8+ T cells with potent lytic activity. To stimulate the breadth, potency, and rate of response required, Profectus Biosciences intends to utilize its platform technologies based on electroporation of DNA vaccines combined with genetic a ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Topically-delivered Mutation-specific Gene Targeting for Epidermolytic Ichthyosis
SBC: Exicure, Inc. Topic: NIAMSDESCRIPTION (provided by applicant): AuraSense Therapeutics (AST), along with Northwestern University, is applying a recently developed technology using oligonucleotide-functionalized nanoparticles (called spherical nucleic acids or SNAs) to control protein expression. These easily synthesized nanoparticles can have either DNA or RNA shells, and are less than 50 nm in hydrodynamic diameter. SNA co ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
BAC Sudoku Sequencing Paradigm to Accelerate Metagenomic Natural Product Chemistr
SBC: LUCIGEN CORPORATION Topic: NCCIHDESCRIPTION (provided by applicant): There is societal need for new compounds in our arsenal of defenses against microbial pathogens, many of which are increasingly resistant to existing therapeutics. The best possible source for new antimicrobial compounds with potentially novel mechanisms of action is within natural environments, particularly soils, which have the greatest diversity of microbial ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health